

ALMIRALL ANNOUNCES AN INITIAL AGREEMENT FOR THE SALE OF ITS PLANT AT SANT JUST DESVERN TO LESVI

Barcelona, 31 July 2008.- Almirall, an international pharmaceutical company with its headquarters in Spain, announces that it has reached an initial agreement for the sale of its pharmaceutical plant at Sant Just Desvern to the pharmaceutical company Lesvi, part of the Icelandic group Invent Farma.

One of the aims of Almirall's Strategic Plan is to consolidate its leadership position in the pharmaceutical sector by focussing on specific strategic objectives. Bearing in mind that Almirall has currently several production facilities (4 pharmaceutical plants and 2 chemical plants), capacity at the Sant Just Desvern plant was not being fully exploited. For this reason a pharmaceutical laboratory was found that would be able to optimise both production capacity and the workforce.

The operation means working and production activity at the plant will continue, with the transfer of job positions. Medicinal products currently manufactured in Sant Just Desvern will still be produced there through an agreement with the company acquiring the facilities.

Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis. Almirall's medicines are currently present in over 70 countries with direct presence in Europe and Latin America in 11 countries.

For further information please visit the website at: www.almirall.com

For further information:
Ketchum SEIS
Sonia San Segundo
91 788 32 00
sonia.sansegundo@ketchum.com